These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 29461155)
1. Cut stroke in half: Polypill for primary prevention in stroke. Brainin M; Feigin V; Martins S; Matz K; Roy J; Sandercock P; Teuschl Y; Tuomilehto J; Wiseman A Int J Stroke; 2018 Aug; 13(6):633-647. PubMed ID: 29461155 [TBL] [Abstract][Full Text] [Related]
2. Polypill Trials for Stroke Prevention-Main Results, Critical Appraisal, and Implications for US Population. Ibraheem M; Goldstein LB Curr Neurol Neurosci Rep; 2020 Apr; 20(5):10. PubMed ID: 32296941 [TBL] [Abstract][Full Text] [Related]
3. A polypill strategy to improve adherence: results from the FOCUS project. Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393 [TBL] [Abstract][Full Text] [Related]
4. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A; Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727 [TBL] [Abstract][Full Text] [Related]
5. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A; Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587 [TBL] [Abstract][Full Text] [Related]
6. Future of polypill use for the prevention of cardiovascular disease and strokes. Chrysant SG; Chrysant GS Am J Cardiol; 2014 Aug; 114(4):641-5. PubMed ID: 24996555 [TBL] [Abstract][Full Text] [Related]
7. The challenge of polypharmacy in cardiovascular medicine. Volpe M; Chin D; Paneni F Fundam Clin Pharmacol; 2010 Feb; 24(1):9-17. PubMed ID: 19817871 [TBL] [Abstract][Full Text] [Related]
8. Polypill: quo vadis? Muscente F; De Caterina R J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194 [TBL] [Abstract][Full Text] [Related]
10. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease. Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850 [TBL] [Abstract][Full Text] [Related]
11. Polypill Variants (Quarter Pill Trials). Teo K; Yusuf S Am J Hypertens; 2018 Jun; 31(7):758-761. PubMed ID: 29554202 [TBL] [Abstract][Full Text] [Related]
12. The concept of the polypill in the prevention of cardiovascular disease. Wiley B; Fuster V Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562 [TBL] [Abstract][Full Text] [Related]
13. Fixed-dose combination treatment after stroke for secondary prevention in China: a national community-based study. Longde W; Ling Y; Yang H; Yi Z; Yongjun W; Xunming J; Xiaoyuan N; Qiumin Q; Li H; Yuming X; Mei L; Jiayi S; Jing L; Dong Z Stroke; 2015 May; 46(5):1295-300. PubMed ID: 25782466 [TBL] [Abstract][Full Text] [Related]
14. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention. Roy A; Naik N; Srinath Reddy K Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033 [TBL] [Abstract][Full Text] [Related]
16. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A; Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449 [TBL] [Abstract][Full Text] [Related]
18. Polypill: Benefits Seen for Stroke and Other Outcomes. Brainin M; Teuschl Y; Martins S Stroke; 2022 Aug; 53(8):2695-2701. PubMed ID: 35726621 [TBL] [Abstract][Full Text] [Related]
19. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy? Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098 [TBL] [Abstract][Full Text] [Related]
20. Polypill strategy for primary prevention of cardiovascular disorders. Dabhadkar KC; Bellam N Drugs Today (Barc); 2013 May; 49(5):317-24. PubMed ID: 23724411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]